2026-01-29 - Analysis Report
**Eli Lilly Company Overview:**
Eli Lilly is a multinational pharmaceutical company that develops, manufactures, and sells medicines for various diseases and conditions.

**Return Rate Comparison:**
The return rate (rate) of Eli Lilly (LLY) is 644.26%, compared to the return rate of S&P 500 (VOO) (rate_vs) of 128.51%. The degree of divergence is 515.75.

**Risk Level and Performance:**
The Market Risk Indicator (MRI) is 0.70, indicating a Medium Risk Level. The relative divergence is 89.50%, indicating that it is located at the top 89.50% percentile of past data. The cumulative return of the review stock is 644.26%, and the cumulative return of the comparison stock (S&P 500, VOO) is 128.51%.

**Alpha, Beta Analysis:**
| Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
| ---  | --- | --- | ---  | --- | ---  |
| 2016-2018 | 46.0% | 14.2% | 38.0% | 0.7 | 101.8B |
| 2017-2019 | 54.0% | 12.1% | 29.0% | 0.7 | 115.6B |
| 2018-2020 | 82.0% | 19.7% | 58.0% | 0.7 | 148.5B |
| 2019-2021 | 128.0% | 19.7% | 64.0% | 0.7 | 242.9B |
| 2020-2022 | 169.0% | 19.7% | 165.0% | 0.7 | 321.7B |
| 2021-2023 | 259.0% | 18.2% | 241.0% | 0.5 | 512.6B |
| 2022-2024 | 349.0% | 23.9% | 320.0% | 0.6 | 678.8B |
| 2023-2025 | 454.0% | 33.4% | 378.0% | 0.7 | 945.0B |

**Recent Stock Price Fluctuations:**
| Figure | Value |
| --- | --- |
| Close | $1039.51 |
| Last-market | -$1.89 |
| 5-day SMA | $1066.49 |
| 20-day SMA | $1067.62 |
| 60-day SMA | $1033.31 |

**RSI and PPO Analysis:**
- Market Risk Indicator (MRI) = 0.70
- RSI = 45.22
- PPO = -0.42
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium
- Recent (20 days) relative divergence change = -1.20 (worsening)
- 7-day Rank change = -1 (rank down)
- 7-day Dynamic Expected Return change = 57.40 (+) improving

**Expected Return:**
Expected Return (%) = 105.90%, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

**Recent News & Significant Events:**
- 2026-01-28: Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership - TipRanks
- 2026-01-28: Hereâ€™s Why Eli Lilly (LLY) is Surging - Yahoo Finance
- 2026-01-28: Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
- 2026-01-28: Eli Lilly inks a gene-editing deal worth up to $1.12B with Seamless - Seeking Alpha
- 2026-01-16: Buy The Dip In LLY Stock? - Forbes
- 2026-01-28: Eli Lilly and Company (LLY): A Bull Case Theory - Insider Monkey

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.77
- Opinions: 28
- Target Price (avg/high/low): 1133.93 / 1500.00 / 770.00

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-30 | 6.22 | $17.60B |
| 2025-08-07 | 6.3 | $15.56B |
| 2025-05-01 | 3.07 | $12.73B |
| 2024-10-30 | 1.08 | $11.44B |

**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

**Capital and Profitability:**
| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.